×
About 17,143 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  6,316 results

HERVs role in the pathogenesis, diagnosis or prognosis of aging diseases: A systematic ...
https://doi.org/10.2174/1566524022666220525144135
Current Molecular Medicine; Prieto-Oliveir P

May 28th, 2022 - HERVs are humans endogenous retroviruses, which represent about 8% of human genome, and have various physiological functions, specially in pregnancy, embryo development and placenta formation. However, their involvement in diseases is not well def...

HLA and amyotrophic lateral sclerosis: a systematic review and meta-analysis.
https://doi.org/10.1080/21678421.2022.2078665
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Nona RJ, Greer JM et. al.

May 27th, 2022 - Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease associated with loss of upper and lower motor neurones. It leads to death by respiratory failure and has a typical prognosis of 2-3 years. The immune system has been sh...

Remote versus face-to-face home-based exercise programme in people with amyotrophic lat...
https://doi.org/10.1136/bmjopen-2021-056323
BMJ Open; Souza AA, Silva STD et. al.

May 27th, 2022 - Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease with variable and complex clinical manifestations that requires a multidisciplinary approach. However, face-to-face treatment in this population may experience barriers...

RiLuzole to Reduce Atrial FIb A Prospective, Double-Blind, Randomized, Placebo-Controlled Study Using Holter Monitoring
https://clinicaltrials.gov/ct2/show/NCT05292209

May 27th, 2022 - Atrial fibrillation (AF) is a growing clinical problem.1 AF is a highly dynamic condition involving episodes of sinus rhythm interspersed with periods of arrhythmia, becoming more difficult to terminate over time. AF carries a substantial cost, mo...

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

May 27th, 2022 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  179 results

RiLuzole to Reduce Atrial FIb A Prospective, Double-Blind, Randomized, Placebo-Controlled Study Using Holter Monitoring
https://clinicaltrials.gov/ct2/show/NCT05292209

May 27th, 2022 - Atrial fibrillation (AF) is a growing clinical problem.1 AF is a highly dynamic condition involving episodes of sinus rhythm interspersed with periods of arrhythmia, becoming more difficult to terminate over time. AF carries a substantial cost, mo...

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

May 27th, 2022 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

Sensitivity and Reproducibility of 18F-fluorodeoxyglucose Positron Emission Tomography for Assessment of Respiratory Muscle Activity
https://clinicaltrials.gov/ct2/show/NCT05234099

May 27th, 2022 - The assessment of respiratory muscle function is critical within both clinical and research settings. Tools for the assessment of respiratory muscle function are especially useful in diagnosing, phenotyping, understanding pathophysiology, and asse...

TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
https://clinicaltrials.gov/ct2/show/NCT04998305

May 24th, 2022 - In Japan, TJ-68 is a common Kampo medicine prescribed by Japanese physicians to manage muscle cramps or pain of diverse origins. In the USA, there are no effective medications to control muscle cramps and no approved medications to specifically tr...

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
https://clinicaltrials.gov/ct2/show/NCT04931862

May 24th, 2022 - This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of intrathecal (IT) WVE-004 in adult patients with C9orf72-associated ALS or FTD. To participate in the study, p...

see more →

News  332 results

FDA Approves Oral Form of ALS Drug Edaravone
https://www.medscape.com/viewarticle/973926

May 13th, 2022 - The US Food and Drug Administration (FDA) has approved an orally administered version of edaravone (Radicava ORS) for adults with amyotrophic lateral sclerosis (ALS).  Edaravone is a pyrazolone free-radical scavenger thought to lessen the effects ...

Ultra-High Dose Drug Slows Functional Decline in Early ALS, Phase 3 Data Show
https://www.medscape.com/viewarticle/973901

May 12th, 2022 - An ultrahigh-dose of methylcobalamin slows functional decline by 43% in patients with early-stage amyotrophic lateral sclerosis (ALS), new research shows. The 50-mg dose was administered twice-weekly via intramuscular injection. In the phase 3 stu...

Researchers Identify Potential Skin Biomarker for ALS
https://www.medscape.com/viewarticle/972630

Apr 22nd, 2022 - This article was originally published in Spanish on Univadis. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons from the cortex, brain stem, and spinal cord. As a result of this disease, motor neurons gradu...

A Biomarker for ALS?
https://www.medscape.com/viewarticle/972539

Apr 21st, 2022 - The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed.  Key Takeaways Results from this study showed plasma phosphorylated tau (p-tau181), was higher in patients with amyotrophic lateral sc...

Neurology Journal Highlights: 6 New Studies
https://www.medscape.com/viewarticle/969715

Apr 18th, 2022 - This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener from the University of Duisburg-Essen in Germany. Today I'd like to discuss six neurology studies that were published recently. Edaravone for Amyotrophic Lateral Sc...

see more →

Patient Education  10 results see all →